Podcasts about therapies

Today on the You Can Heal Your Life Podcast, we're sharing a chapter from David Hamilton's audiobook Why Woo-Woo Works. David discusses the compelling evidence of why and how alternative therapies work and explains the science and spirituality behind popular alternative practices. You can listen to the full audiobook FREE for 14 days in the Empower You Unlimited Audio App. To download it today, Apple users visit hayhouse.com/apple and Android users visit hayhouse.com/google

In this program Dr. Anderson will answer questions about some of the more interesting therapeutics in the integrative, naturopathic and natural medicine world. Hyperbaric Oxygen, Intravenous Nutrient Therapy, Photodynamic Therapies, Sauna and Hyperthermia, Neurofeedback and other modalities will be discussed. This is an extension of last week's program where the more common "base" therapies were discussed.

Michaela E. Wermers, PharmD, defines therapeutic options and appropriate dosing methods for oral iron replacement, identifies the various intravenous iron therapies and discuss product differences, reviews literature of select disease states in which intravenous iron therapy is utilized. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter! You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.   

The use of oral therapies for chronic lymphocytic leukemia has had a great impact on patient outcomes and quality of life. Pharmacists can play a key role in assisting with therapy selection, education for patients and the healthcare team, and also managing adverse effects for patients receiving these therapies. Objectives Differentiate novel therapies for the treatment of chronic lymphocytic leukemia (CLL) by pharmacologic properties and special considerations for use Associate drug therapy and safety and efficacy information with treatment selection for patients with CLL Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida. Dr. Tobon has no relevant financial relationships with commercial interests to disclose. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode I briefly go over 3 forms of alternative therapy methods. EFT Tapping, CBT therapy, and EMDR therapy. Hope this helps ❤️ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/ashleyelysian/message Support this podcast: https://anchor.fm/ashleyelysian/support

Peter Michalos MD - New life-extending therapies. Life and quality of life. by John Catsimatidis

In this program Dr. A will answer questions about diet, nutrients, herbs, sleep, movement, interventional therapies, and more!

Too many kidney patients face significant barriers to accessing lifesaving care. Research shows longer, more frequent dialysis done in the home yields better kidney health outcomes and improved quality of life for patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Yet, patients do not have equal access to this treatment option. Join us as we unpack disparities in today's kidney disease treatment paradigm and discuss the steps, we, as nephrologists, need to take to alleviate access issues and help make the options of in-home treatment a reality for more patients.      

Welcome back for the follow-up to episode 70 and the conclusion of my interview with Corey Gauthier.   In our last episode, Corey discussed his journey into plant medicines and psychedelic therapies after realizing that his "live fast, die young" lifestyle had some deep-rooted trauma. For those who missed it, I strongly encourage you to check it out first! Today, we're going to continue along on our journey with him.   Here are three reasons why you should listen to the full episode: Listen to Corey's personal experience with an African Rites of Passage ceremony, as well as the incredible story that gave me goosebumps. Discover why the Sacred Soul Center closed its doors. Hear Corey's recommendations for plant medicine clinics.   Are you enjoying the Hard Beautiful Journey podcast?   Click here to follow on Apple Podcasts. While there, please leave a 5-star rating and review; it would mean so much to me! Also, if you haven't done so already, join the Hard Beautiful Journey community to connect with other like-minded people.   I  would love to connect with you on social, so please give me a follow on: Instagram Facebook YouTube LinkedIn   Thanks for listening, Tiff

For this “ABCs of NMOSD” podcast titled "Long-Term Therapies in NMOSD," SRNA's Dr. GG deFiebre was joined by Dr. Dean M. Wingerchuk. Dr. Wingerchuk began by explaining the difference between acute versus long-term treatments and providing an overview of the most common long-term treatments for NMOSD. He then discussed side effects and effectiveness. Finally, Dr. Wingerchuk provided information on factors to consider when someone is considering which long-term treatment to use, including antibody testing, approval from medical insurance, and relapse occurrence.

Commentary by Dr. Avirup Guha

Today, Corey Gauthier joins me for the first part of our conversation about how he began his journey into plant medicines and psychedelic therapies after realizing that his "live fast, die young" lifestyle had some deep-seated trauma attached to it.   This journey would lead him to a world he had never known existed and eventually to his new career as a plant medicine entrepreneur.    Come back on Thursday, June 23, to hear the episode's conclusion, where Corey tells a story about a trip to Africa that gave me goosebumps. You won't want to miss it.    Here are three reasons why you should listen to the full episode: Corey wanted to devote his life to the powerful healing properties of plant medicines. Learn how this journey led him down a path that expanded his world in ways he never imagined possible. Discover how, once the stigma surrounding "modern recreational drugs" is removed, they have a powerful place in our modern-day on a micro-dosing or therapeutic purpose. Full Show Notes Here! Click here to follow on Apple Podcasts. While there, please leave a 5-star rating and review; it would mean so much to me! Also, if you haven't done so already, join the Hard Beautiful Journey community to connect with other like-minded people.   I would love to connect with you on social, so please give me a follow on:   Instagram Facebook YouTube LinkedIn   Thanks for listening, Tiff

Drug developers face long odds and complex regulatory challenges when it comes to crafting a suitable candidate. In fact, only one of every 10 drug candidates gain regulatory approval, and when they do, it takes an average of 14 years and costs well over $2 billion.   So what makes for a successful candidate? It starts with a suitable screening platform that identifies targets and the molecules that bind to them to create a therapeutic response. Retrogenix is one such platform that the top 20 drug developers in the world currently use to increase their chances of success thanks to its unique technology that doesn't require animal models or human tissue to evaluate effectiveness.   Join us to find out how Retrogenix works to identify targets, accelerate drug development, get vulnerable patients the therapies they need more quickly, and adapt to meet the growing demands of regulatory agencies. Show Notes  Charles River Acquires Retrogenix  Retrogenix Cell Microarray Technology  De-risking Therapies and Vaccines for Use During Pregnancy  Assessing ADC Anticancer Therapeutics via Antibody Specificity Screening  Screening and Profiling Assays  Off-Target Screening Cell Microarray Assay   Webinar: Building a comprehensive lead enabling library   Poster: Off-target Assessment of Biotherapeutics for us During Pregnancy  Case Study: Antibody Drug Conjugate Off-Target Binding Screen

In this bonus episode, Kyle interviews Dr. Scott Shannon: Co-Founder and CEO of the Board of Psychedelic Medicine and Therapies; a non-profit created to certify healthcare professionals in psychedelic-assisted psychotherapy.  www.psychedelicstoday.com

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Go online to PeerView.com/ASX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best strategies for integrating novel therapeutic approaches into the care of your patients with renal cell carcinoma (RCC)? With the rapid expansion of effective treatments, oncology nurses have more opportunities than ever before to provide support and guidance that favorably influences outcomes for their patients with advanced kidney cancer. However, research has shown that many patients are not receiving individualized, evidence-based, and guideline-concordant treatment and those patients who are receiving new therapies are not receiving appropriate nurse-led care. Join PeerView for an interprofessional case-based activity featuring two nurse professionals and an oncologist to get insight on bringing treatment advances, including immune checkpoint inhibitors and combination strategies, into clinical practice. The expert panel will provide learners with a strong understanding of how current therapeutic regimens fit within the current management paradigm. Participants will also be offered tools to help them master practical aspects tied to effective use of therapies and tips on how to create optimized interprofessional care that empowers patients to participate in shared decision-making, provide multidisciplinary AE management, and support clinical trial enrollment for eligible patients. Upon completion of this activity, participants should be better able to: Appraise recent data on therapeutic advances and updated practice standards, including the use of immune checkpoint inhibitors, TKIs, and combination approaches utilizing these agents, in the management of RCC across the disease spectrum, Update nursing care plans to incorporate practical and team-based strategies to promptly identify, mitigate, and manage AEs associated with novel systemic therapy options for RCC, Develop a team-based education plan focused on novel systemic therapy options for patients with RCC that includes pertinent information on therapeutic expectations, safety considerations, sequential treatments, and clinical trial opportunities.

Dr. Diem Nguyen is the CEO of Xalud Therapeutics, a DNA delivery gene therapy company striving to develop and deliver medicines for large, broad-based disease indications like chronic inflammatory diseases, particularly musculoskeletal diseases like osteoarthritis of the knee and as well as neurodegenerative diseases like MS and ALS. Earlier in her career, Diem was the global President of Pfizer, covering multiple therapeutic areas, and has joined Xalud because of their ground-breaking DNA delivery platform. Diem explains, "Gene therapy means a lot of things to a lot of people. And the first, I would say, is most people, when they think about gene therapies, think about viral AAV gene therapy. And a lot of promise is associated with that type of platform because you're seeing this potential, particularly in rare diseases. The challenges associated with AAV sometimes are the safety profile associated with that product. Our particular gene therapy is DNA gene therapy, so we do not have the challenges with genome integration, which allows us to have a potentially stronger safety profile." "I want to be very clear when I say disease modification because it can mean many things from a definition perspective to different audiences. What I want to say specifically about our product, XT-150, is we're not looking to treat pain associated with osteoarthritis of the knee by just blocking the pain or masking the pain. What we're trying to do is help your body restore homeostasis." "What we're saying is we're supplementing your body with interleukin-10, which then allows you to have your body naturally reduce pro-inflammatory cytokines, which then reduces the inflammation." #XaludTherapeutics #GeneTherapy #InflammatoryDiseases #Cytokines #Inflammation #Osteoarthritis #NeurodegenerativeDiseases #ALS #MS XaludThera.com Listen to the podcast here

Dr. Diem Nguyen is the CEO of Xalud Therapeutics, a DNA delivery gene therapy company striving to develop and deliver medicines for large, broad-based disease indications like chronic inflammatory diseases, particularly musculoskeletal diseases like osteoarthritis of the knee and as well as neurodegenerative diseases like MS and ALS. Earlier in her career, Diem was the global President of Pfizer, covering multiple therapeutic areas, and has joined Xalud because of their ground-breaking DNA delivery platform. Diem explains, "Gene therapy means a lot of things to a lot of people. And the first, I would say, is most people, when they think about gene therapies, think about viral AAV gene therapy. And a lot of promise is associated with that type of platform because you're seeing this potential, particularly in rare diseases. The challenges associated with AAV sometimes are the safety profile associated with that product. Our particular gene therapy is DNA gene therapy, so we do not have the challenges with genome integration, which allows us to have a potentially stronger safety profile." "I want to be very clear when I say disease modification because it can mean many things from a definition perspective to different audiences. What I want to say specifically about our product, XT-150, is we're not looking to treat pain associated with osteoarthritis of the knee by just blocking the pain or masking the pain. What we're trying to do is help your body restore homeostasis." "What we're saying is we're supplementing your body with interleukin-10, which then allows you to have your body naturally reduce pro-inflammatory cytokines, which then reduces the inflammation." #XaludTherapeutics #GeneTherapy #InflammatoryDiseases #Cytokines #Inflammation #Osteoarthritis #NeurodegenerativeDiseases #ALS #MS XaludThera.com Download the transcript here

On today's episode, meet Dr. Danny Nguyen. Dr. Nguyen is a Medical Oncologist and Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research at City of Hope in California. He is passionate about treating patients in the community setting close to where they live. Danny completed fellowship training in oncology and hematology at H. Lee Moffitt Cancer Center, his residency in internal medicine at Emory University and medical school at the University of South Florida. He aims to reduce disparities in cancer care by improving access to innovative therapies through clinical trials for the Orange County community.

Strategies to replace or compensate for mutated copies of the TCF4 gene could lead to treatments for this profound form of autism, a new study suggests. The post Organoids test gene therapies for Pitt-Hopkins syndrome appeared first on Spectrum | Autism Research News.

Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Do we love our subscribers and listeners? Absolutely. Do we like to release cool bonus content for them to be better physicians? Yes of course. Let's dive in to the details on all you need to know with acute gout therapies in

Jill Nicolini Interviews Alyssa Campbell Speech Language Pathologist and Owner of Alyssa Campbell Therapies -- ww.alyssacampbelltherapies.comhttps://onlineradiobox.com/search?cs=us.pbnnetwork1&q=podcast%20business%20news%20network&c=ushttps://mytuner-radio.com/search/?q=business+news+network

NASH has historically had very few treatment options, with none currently indicated specifically for NASH. But a large number of ongoing clinical trials means that treatment may look different in the future. Join Professor Philip Newsome for an overview of current treatments in NASH, as well as how treatment may change in the future. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: References are available here Disclosures: Prof. Philip Newsome declares the following: Consultant on behalf of the University of Birmingham: Boehringer Ingelheim, Novo Nordisk, Intercept, BMS, Gilead, Poxel Pharmaceuticals Grants/Research Support recipient: Novo Nordisk, Boehringer Ingelheim Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. Funding: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Session ‘Update on Adjunctive Sepsis and COVID-19 Therapies' from the 2022 WSC Spotlight. Featuring Evangelos J. Giamarellos-Bourboulis, Alexander Vlaar, Luregn Schlapbach, Sarah Sasson, and Luis Antonio Gorordo Del Sol as your moderator.

Dr. Merhi comes back and this time he talks to us about At Home IVF and Ozone Sauna. He discusses who might benefit from these treatment options. Dr. Merhi helped create the At Home IVF system where you can get your stimulation medications without injections, monitoring or labs. He explains this further as not all patients are candidates for this method of IVF. We also discuss another treatment option that might be beneficial for those who are 40 and over or for those who might need help with egg quality. Resources: Rejuvenating Fertility Center: https://www.rejuvenatingfertility.com/ Dr. Zaher Merhi: https://www.instagram.com/dr_merhi/ Dr. Aimee Eyvazzadeh: https://www.instagram.com/eggwhisperer/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/40andinfertile/support

Could RPE cell replacement therapy be the future of GA treatments? Retina Today's Chief Medical Editor Allen C. Ho, MD, joined us to discuss observations from a phase 1/2a study evaluating the safety and efficacy of OpRegen (Lineage Cell Therapeutics), a suspension of allogenic RPE cells implanted in the subretinal space. How well was this therapy tolerated, and were there any signs of vision improvement?   Elsewhere in the GA pipeline, researchers are exploring whether the gene therapy GT005 (Gyroscope Therapeutics) might be a safe and effective one-time treatment for GA via upregulation of complement factor I. How does complement factor I affect the course of GA, and what are the latest data from a phase 1/2 study? Check out this episode to hear on conversation on that topic with Jared Nielsen, MD, MBA.   This podcast is editorially independent, supported with advertising.

ONCE UPON A GENE - EPISODE 137 Advancing Therapies for Rare Liver Diseases and Alagille Syndrome with FDA Approved LIVMARLI with Chris Peetz - CEO of Mirum Pharmaceuticals Chris Peetz is the CEO of Mirum Pharmaceuticals, a pharmaceutical company focused on rare liver diseases. They work closely with patients and advocacy groups and have genuine connections which reinforces their sense of urgency to create treatments for liver-related diseases and help to make lives better.  EPISODE HIGHLIGHTS How was Mirum founded? Our current programs include two different medicines. LIVMARLI (maralixibat) is for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and another is currently in development for other liver conditions. These programs were being developed by a larger company who decided not to work further on the program. Our co-founder had a relationship with families involved with the clinical studies of maralixibat and, upon seeing how good the patients were doing, decided to start the company and get the program back on course.  What does LIVMARLI do and what symptoms does it treat for Alagille patients? LIVMARLI is an oral liquid medicine that blocks the absorption of bile acids in the GI tract. In clinical studies, we've seen the itch that patients experience improves.  How do you decide what rare diseases to focus on and what's in the Mirum pipeline? We're currently focused on broadening access to LIVMARLI for ALGS patients and taking what we've learned and applying it to other liver diseases that have similar issues with bile acids.  How can rare disease advocacy groups help to push to get treatments approved? The impact patient groups have in working through the regulatory process is massive. They play a big role in providing a voice and awareness to help educate regulators. Patient groups do a lot to educate regulators, but also researchers so they can better understand the complex aspects of a rare disease. LINKS & RESOURCES MENTIONED Once Upon a Gene TV https://www.thedisordercollection.com/ ONCE UPON A GENE - EPISODE 036 - Anna Laurent on Alagille Syndrome and Her Road to Advocacy https://effieparks.com/podcast/episode-36-anna-laurent-alagille-syndrome Mirum Pharmaceuticals https://mirumpharma.com/ Mirum Access Plus https://www.livmarli.com/ The Alagille Syndrome Alliance https://alagille.org/ ClinicalTrials https://clinicaltrials.gov/ TUNE INTO THE ONCE UPON A GENE PODCAST Spotify https://open.spotify.com/show/5Htr9lt5vXGG3ac6enxLQ7 Apple Podcasts https://podcasts.apple.com/us/podcast/once-upon-a-gene/id1485249347 Stitcher https://www.stitcher.com/podcast/once-upon-a-gene Overcast https://overcast.fm/itunes1485249347/once-upon-a-gene CONNECT WITH EFFIE PARKS Website https://effieparks.com/ Twitter https://twitter.com/OnceUponAGene Instagram https://www.instagram.com/onceuponagene.podcast/?hl=en Built Ford Tough Facebook Group https://www.facebook.com/groups/1877643259173346/

Despite the Talmud being the richest repository of medical remedies in ancient Judaism, this important strain of Jewish thought has been largely ignored – even as the study of ancient medicine has exploded in recent years. In a comprehensive study of this topic, Jason Sion Mokhtarian recuperates this obscure genre of Talmudic text, which has been marginalized in the Jewish tradition since the Middle Ages, to reveal the unexpected depth of the rabbis' medical knowledge. Medicine in the Talmud: Natural and Supernatural Therapies Between Magic and Science (U California Press, 2022) argues that these therapies represent a form of rabbinic scientific rationality that relied on human observation and the use of nature while downplaying the role of God and the Torah in health and illness. Drawing from a wide range of both Jewish and Sasanian sources – from the Bible, the Talmud, and Maimonides to texts written in Akkadian, Syriac, and Mandaic, as well as the incantation bowls – Mokhatarian offers rare insight into how the rabbis of late antique Babylonia adapted the medical knowledge of their time to address the needs of their community. In the process, he narrates an untold chapter in the history of ancient medicine. Rachel Pagones is an acupuncturist, educator, and author based in Cambridge, England. Her book, Acupuncture as Revolution: Suffering, Liberation, and Love (Brevis Press) was published in 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Despite the Talmud being the richest repository of medical remedies in ancient Judaism, this important strain of Jewish thought has been largely ignored – even as the study of ancient medicine has exploded in recent years. In a comprehensive study of this topic, Jason Sion Mokhtarian recuperates this obscure genre of Talmudic text, which has been marginalized in the Jewish tradition since the Middle Ages, to reveal the unexpected depth of the rabbis' medical knowledge. Medicine in the Talmud: Natural and Supernatural Therapies Between Magic and Science (U California Press, 2022) argues that these therapies represent a form of rabbinic scientific rationality that relied on human observation and the use of nature while downplaying the role of God and the Torah in health and illness. Drawing from a wide range of both Jewish and Sasanian sources – from the Bible, the Talmud, and Maimonides to texts written in Akkadian, Syriac, and Mandaic, as well as the incantation bowls – Mokhatarian offers rare insight into how the rabbis of late antique Babylonia adapted the medical knowledge of their time to address the needs of their community. In the process, he narrates an untold chapter in the history of ancient medicine. Rachel Pagones is an acupuncturist, educator, and author based in Cambridge, England. Her book, Acupuncture as Revolution: Suffering, Liberation, and Love (Brevis Press) was published in 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Despite the Talmud being the richest repository of medical remedies in ancient Judaism, this important strain of Jewish thought has been largely ignored – even as the study of ancient medicine has exploded in recent years. In a comprehensive study of this topic, Jason Sion Mokhtarian recuperates this obscure genre of Talmudic text, which has been marginalized in the Jewish tradition since the Middle Ages, to reveal the unexpected depth of the rabbis' medical knowledge. Medicine in the Talmud: Natural and Supernatural Therapies Between Magic and Science (U California Press, 2022) argues that these therapies represent a form of rabbinic scientific rationality that relied on human observation and the use of nature while downplaying the role of God and the Torah in health and illness. Drawing from a wide range of both Jewish and Sasanian sources – from the Bible, the Talmud, and Maimonides to texts written in Akkadian, Syriac, and Mandaic, as well as the incantation bowls – Mokhatarian offers rare insight into how the rabbis of late antique Babylonia adapted the medical knowledge of their time to address the needs of their community. In the process, he narrates an untold chapter in the history of ancient medicine. Rachel Pagones is an acupuncturist, educator, and author based in Cambridge, England. Her book, Acupuncture as Revolution: Suffering, Liberation, and Love (Brevis Press) was published in 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Despite the Talmud being the richest repository of medical remedies in ancient Judaism, this important strain of Jewish thought has been largely ignored – even as the study of ancient medicine has exploded in recent years. In a comprehensive study of this topic, Jason Sion Mokhtarian recuperates this obscure genre of Talmudic text, which has been marginalized in the Jewish tradition since the Middle Ages, to reveal the unexpected depth of the rabbis' medical knowledge. Medicine in the Talmud: Natural and Supernatural Therapies Between Magic and Science (U California Press, 2022) argues that these therapies represent a form of rabbinic scientific rationality that relied on human observation and the use of nature while downplaying the role of God and the Torah in health and illness. Drawing from a wide range of both Jewish and Sasanian sources – from the Bible, the Talmud, and Maimonides to texts written in Akkadian, Syriac, and Mandaic, as well as the incantation bowls – Mokhatarian offers rare insight into how the rabbis of late antique Babylonia adapted the medical knowledge of their time to address the needs of their community. In the process, he narrates an untold chapter in the history of ancient medicine. Rachel Pagones is an acupuncturist, educator, and author based in Cambridge, England. Her book, Acupuncture as Revolution: Suffering, Liberation, and Love (Brevis Press) was published in 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/religion

Despite the Talmud being the richest repository of medical remedies in ancient Judaism, this important strain of Jewish thought has been largely ignored – even as the study of ancient medicine has exploded in recent years. In a comprehensive study of this topic, Jason Sion Mokhtarian recuperates this obscure genre of Talmudic text, which has been marginalized in the Jewish tradition since the Middle Ages, to reveal the unexpected depth of the rabbis' medical knowledge. Medicine in the Talmud: Natural and Supernatural Therapies Between Magic and Science (U California Press, 2022) argues that these therapies represent a form of rabbinic scientific rationality that relied on human observation and the use of nature while downplaying the role of God and the Torah in health and illness. Drawing from a wide range of both Jewish and Sasanian sources – from the Bible, the Talmud, and Maimonides to texts written in Akkadian, Syriac, and Mandaic, as well as the incantation bowls – Mokhatarian offers rare insight into how the rabbis of late antique Babylonia adapted the medical knowledge of their time to address the needs of their community. In the process, he narrates an untold chapter in the history of ancient medicine. Rachel Pagones is an acupuncturist, educator, and author based in Cambridge, England. Her book, Acupuncture as Revolution: Suffering, Liberation, and Love (Brevis Press) was published in 2021. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/jewish-studies

Can methylphenidate help amphetamine and methamphetamine use disorder? This episode discusses stimulant replacement therapies for methamphetamine and amphetamine use disorder. This includes the possible use of MPH in patients with underlying ADHD.  Faculty: Andrew Saxon, M.D.  Host: Jessica Diaz, M.D. Learn more about Premium Membership here Earn 1 CME: Experimental Pharmacotherapies for Stimulant Use Disorder Stimulant Replacement Therapies for Methamphetamine and Amphetamine Use Disorder

Morgan White Jr. fills in on NightSide with Dan Rea:The CDC reports that in the U.S., 37.3 million people (11.3% of the population) have diabetes, and 96 million (38.0%) over the age of 18 have prediabetes. Although there is no cure for diabetes, there are many ways it can be controlled for optimal health. Dr. David Nathan, Director of the Diabetes Center and Clinical Research Center at Massachusetts General Hospital, joins Morgan to answer all your questions!

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Research from AsIAm has indicated that almost 270 children do not have appropriate places available to them for the new school year. Campaign groups are calling for the rights of these children to be upheld. Miriam Kenny is Chairperson of Involve Autism, and special needs teacher Audrey, joined Anton to discuss the lack of educational supports and the impact it can have on children.

I am a person who never gives up, always believing there is hope, and you can change whatever it is. But what if you have symptoms that don't go away, even after you tried so many things? Will you keep looking, or will there be a moment that it's time to accept that this is it, to just enjoy the moment and be grateful for what you have? What is The Concussion Community? We help people with a concussion to not feel alone, recover faster, and to regain their life. Free eBook: "7 things that helped me the most": www.theconcussioncommunity.com Follow me on Instagram: @theconcussioncommunity Is this podcast helpful for you? You would really help me by leaving a review. The more reviews this podcast will get, the easier it is for other people to find it and to feel less alone and lost in their journey.

Cholangiocarcinoma—or biliary duct cancer—affects about 8000 US patients a year. On this episode of Managed Care Cast, we bring you an excerpt of an interview with Jesper B. Andersen, PhD, associate professor and group leader at the University of Copenhagen and the Biotech Research and Innovation center at the Department of Health. There have been 3 FDA drug approvals for drugs that treat cholangiocarcinoma, but only for patients that have certain mutations or rearrangements, signifying an unmet need, noted Andersen. And due to the limited number of patients, clinical trials are challenging. Dr Anderson spoke recently with Brielle Benyon, senior editor of CURE®, a publication by MJH Life Sciences. You can watch this interview and many others with by Visiting Medicalworldnews.com, where you can get expert insights you won't find anywhere else.

This was such a great talk! Here is an overview… Mold Related Illness treatments can be similar because they address root inflammation issues. Step 1: Open inflammation pathways Step 2: Detox phases Step 3: Binders Do you have Lyme? Here is Michelle's recommended order of treatment. Step 1: Begin treating for mold Step 2: Get out of / fix your moldy environment Step 3: Treat Lyme How to think about your contents and belonging and what to do about them. A breakdown on hyperthermia treatment. Enjoy! — @MoldFinders Not sure the best way to get started? Follow these simple steps to hit the ground running... Step 1: Subscribe To This Podcast (and please leave a review!) Step 2: Find Out What Your ERMI Actually Means ERMICode.com Step 3: Get The Training MoldFindersMethod.com Step 4: Text Me (yes it's really me!) The Mold Phone: 949-528-8704 Step 5: Get An Inspection from We Inspect: YesWeInspect.com

Depression, or what is termed medically as major depressive disorder (MDD), is so incredibly multi-faceted that there isn't just one path to healing for everyone who has it.  And yes, you can heal from depression.  There is a small genetic role ~ about 1/3rd of it in some twin studies, but the other 2/3rds is largely environmental, situational, biological, generational, nutritional, spiritual, emotional, metabolic, immune, and so much more.   I talk a little about my experience healing from depression, as a physician, and what it all meant for me.   And then I discuss some of the lesser known therapies (outside of the standard of care of anti-depressants and therapy) that have been studied for major depressive disorder, including acupuncture, hypnosis, aromatherapy, light therapy, saffron, and st. john's wort. Shownotes HERE -------------------------------------------------------------- Our Brain Health Integrative Guide is gone, to make room for a FREE Integrative Wellness Course Module on "How To Aromatherapy for Women's Wellness". All for Free. My presentation and handout on how to become your own aromatherapist for some of the most common conditions that we have to deal with as women! The science behind aromatherapy, precautions, and how to make your own topical, diffusion, sprays, bath salt blends! Worth $100! All for FREE. For a very limited time, so get it today at www.healthispowher.com. Link Below: You can sign up here! ---------------------------------------------------------------- We hope you enjoy the episode and if you do, please SUBSCRIBE, RATE, and REVIEW So you can help us increase our reach to help more women awaken their best selves, have more energy, and live the life they dreamed of while healing and recovering from any pain and health issues! ---------------------------------------------------------------- Be on the lookout for the foundational coaching masterclasses this coming new year! And for those of you ready to heal from a chronic condition, we will have your advanced master coaching program coming soon for Menopause, PCOS, Endometriosis, Pelvic Pain, Hormone Regulation, Autoimmune Disease, Chronic Fatigue, Fibromyalgia, and More!  We will be launching one of these come 2022, so be on the lookout or email us at hello@healthispowher.com to get on the list! ---------------------------------------------------------------- DISCLAIMER Anna Esparham, M.D.is a medical doctor, but she is not your doctor, and she is not offering medical advice on this podcast. If you are in need of professional advice or medical care, you must seek out the services of your own doctor or health care professional. The opinions of podcast guests are not necessarily those of Dr. Esparham, MD and Health Is PowHer, LLC and do not represent her or the company.  This podcast provides information only, and does not provide any financial, legal, medical or psychological services or advice. None of the content on this podcast prevents, cures or treats any mental or medical condition. You are responsible for your own physical, mental and emotional well-being, decisions, choices, actions and results. Health Is PowHer, LLC disclaims any liability for your reliance on any opinions or advice contained in this podcast.  

Coupon Code LTH at www.n1o1.com for the listener discount!